The Genetics Institute Alumni: Where Are They Now?
Luke Timmerman3/22/10Follow @ldtimmerman
[Updated: 11:50 am, 8/27/12] Genetics Institute stopped making biotech headlines a long time ago. But almost 15 years after it was acquired, this high-flier from the industry’s first big wave in the 1980s is still having a ripple effect on the Boston biotech scene. It was one of the key companies that recruited, inspired, and mentored a generation of young scientists and business people in Boston.
GI, as it is known, was founded in 1980 by a couple of scientists from Harvard University, Mark Ptashne and Tom Maniatis, and got going as a business the next year with the addition of Gabriel Schmergel, a former Baxter Healthcare executive, as CEO. The company developed a reputation for first-rate science along with Genentech, another industry pioneer. It grew to 600 employees and a $1 billion market valuation by 1991, before its devastating loss in a patent lawsuit with Amgen. Rather than resort to mass layoffs, GI sold a majority ownership stake to Wyeth in 1992, and was then taken over completely in December 1996. At the end of its independence, 1,200 people worked at Genetics Institute.
Many of the people who now lead emerging biotech companies in Boston—Tuan Ha-Ngoc of Aveo Pharmaceuticals, Adelene Perkins of Infinity Pharmaceuticals, and John Knopf of Acceleron Pharma, to name a few—got their start at Genetics Institute. They still rave about what an amazing experience it was, and how the things they learned there influence them today in how they run their companies.
“This is something I’m particularly proud of,” says Schmergel, reached at his home in Florida. “A whole bunch of people have spun out of there. Some have done incredibly well. And this is a tough business.”
Schmergel—an investor in Xconomy, it must be noted—says Ptashne and Maniatis deserve the credit for establishing a culture that valued top-notch science. But even though he sometimes struggled to understand all of the science himself, he made sure that everybody in the company, not just scientists, respected it. “I used to tell our business guys that you don’t have to be a scientist in biotech, but you better be science-friendly and learn as much as you can because it’s the basis of the company,” Schmergel says.
To get a sense of where the Genetics Institute family tree extends today, I’ve sought to put together a directory with links to help GI alumni connect and re-connect. I want this list to include not just mover-shaker types, but also the rank-and-file who have moved on to other places since the Wyeth takeover in December 1996. The list includes 270 names at last count, and I expect it to grow over time. I owe thanks for help with this project to Schmergel, Infinity’s Perkins, Gina Nugent of The Yates Network, and three guys from Acceleron Pharma—Bob Steininger, Matt Sherman, and Jack Morgan.
Now here’s the part where you can help. If you see any information below that’s out of date or incorrect, please let me know and I’ll fix it. If you have any questions, comments, or new information, please send me a note at ltimmerman@xconomy.com or editors@xconomy.com.
Over time, I hope this story can become a richer and more valuable resource for Genetics Institute alumni. Here’s the list I’ve put together in alphabetical order, with the most updated titles and affiliations I found online.
Joan Abrams, biotechnology teacher, Cambridge Public Schools
Kate Adams, vice president of diagnostics marketing, HistoRx
Robert Adamson, retired, former vice president, Pfizer
Tim Ahern, science and regulatory consultant, Acceleron Pharma
Leslie Alessandri, scientist, Abbott Bioresearch Center [Added: 10:40 am, 5/20/10]
Dean Alger, senior director, regulatory affairs, Genzyme. Retiring in May. [Added: 10:05 am, 3/23/10]
Jayne Allard, US Benefits & Retirement Specialist at Lonza [Added: 5:30 pm, 10/28/11]
Joel Alvarez, associate director, global regulatory operations, Shire Human Genetic Therapies
Juan Alvarez, senior director, discovery research and biologics, Alkermes [Added: 9:45 pm, 3/22/10]
John Amari, associate director, Syntonix Pharmaceuticals, a subsidiary of Biogen Idec [Added: 12:05 am, 4/2/10]
Godfrey Amphlett, executive director, process and product development, ImmunoGen [Added: 12:05 am, 4/2/10]
Kim Archer, project manager, Novartis Institutes for Biological Research
Fred Bader, retired former vice president, Johnson & Johnson
Adel Bakhtyari, senior analytical scientist, Paratek Pharmaceuticals [Added: 3:20 pm, 8/8/11]
Mary Lynn Baniecki, fellow, Harvard Medical School [Added: 2:25 pm, 8/10/10]
Kathleen Beach, director, GlaxoSmithKline
Joan Bell, global head, program office, Novartis
Dennis Benjamin, senior director, chemistry, Seattle Genetics
Leslie Benthien, director of global training, BioMarin Pharmaceuticals
David Berstein, senior vice president and chief intellectual property officer, Ariad Pharmaceuticals
Bernadine Blacknall (Kirkland), senior administrative associate, scientific alliances & research, global medical affairs, Millennium: The Takeda Oncology Company [Updated: 3:20 pm, 10/19/11]
Dale Blank, biotechnology consultant
Garen Bohlin, executive vice president, Constellation Pharmaceuticals
Page Bouchard, global head, preclinical safety, Novartis
Ron Branning, vice president, corporate quality assurance, Gilead Sciences
David Brazier, associate director, clinical operations, New England Research Institutes
Sue Brodeur, associate director, technical operations, Pfizer [Added: 1:35 pm, 3/25/10]
Jonathan Brooks, research scientist II, Pfizer [Added: 12:30 pm, 3/29/10]
Eugene (Gene) Brown, managing member, Quicksilver Consultants
Scott Brown, vice president, general counsel, Novartis Institutes for BioMedical Research [Added: 4:38 pm, 8/1/10]
Tim Bugbee, director, manufacturing, Pfizer [Added: 7:45 pm, 3/23/10]
Paul Burgess, vice president of intellectual property, BIND Biosciences, director of intellectual property, Logical Therapeutics [Added: 10:30 am, 3/26/10]
Kathy Byington, vice president, finance and administration, University of Maryland Baltimore [Added: 7:15 pm, 4/18/10]
Ray Camphausen, associate vice president, protein design, Adnexus Therapeutics
Barbara Carter, biotech human resources consultant
Martha Carter, senior vice president of regulatory affairs and quality assurance, Proteon Therapeutics
Anthony Celeste, research investigator, Array BioPharma [Added: 12:20 am, 4/23/10]
Catherine Celingant, senior director, medical systems innovative technologies, Millennium: The Takeda Oncology Company
Abbie Celniker, CEO, Taligen Therapeutics
Maria Cervone, informatics project manager, center for biomedical informatics, Harvard Medical School
Divya Chaudary, consultant, Nimbus Discovery [Added: 3:35 pm, 10/19/11]
Gustav Christensen, president and CEO, Dyax
Michael Cicio, senior director of manufacturing, Lonza Biologics
Chuck Cifuni, senior project manager, process transfer and manufacturing, pharmaceutical science R&D, Pfizer [Added: 11:35 am, 4/5/10]
Steve Clark, board member, Aveo Pharmaceuticals
Denis Clifford, vice president and chief marketing officer, SBLI
Gary Cohen, biotech attorney specializing in IP and ethics, Foundation Medicine
Robert Corcoran, vice president of quality operations, Shire Human Genetic Therapies
Richard Covitz, president, Oncology Partners
Lisa Cozza, senior director of manufacturing alliances, Human Genome Sciences
Lori Crane, non clinical development sciences, Millennium: The Takeda Oncology Company
Christopher Crowley, senior technology scientist II, Pfizer [Added: 2 pm, 4/2/10]
Luann Cserr, Principal, Cserr Patents & Strategic Counseling [Added: 11/23/10]
Cristina Csimma, vice president of drug development, Virdante Pharmaceuticals
Zoltan Csimma, senior vice president and chief human resources officer, Genzyme
Dale Cumming, director of scientific evaluations, International Consortium on Anti-Virals
Tim Cunningham, senior manufacturing supervisor, Biolex
Rosemarie Currier, contract administrator, EnerNOC [Added: 6:40 pm Eastern, 9/27/10]
Klaus Dahl, retired [Added: 2 pm, 4/2/10]
Stan Daley, retired [Added: 12:30 pm, 3/29/10]
Karen Dawes, president, Knowledgeable Decisions. Board member, Repligen and Depomed
Dawn Day, manager, sales systems and reporting, Novartis Vaccines & Diagnostics
Charlene (Quinto) DeClercq, senior research scientist, inflammation & immunology, Pfizer. [Added: 9:35 am, 1/24/11]
Tom DesRosier, senior vice president and general counsel, Genzyme
Andrew Dorner, senior director, Millennium: The Takeda Oncology Company
Deb Donaldson, translational medicine specialist in the San Francisco Bay Area
Eileen Dube, owner, Merrimack Valley Acupuncture
Kevin Dykstra, president and CEO, qPharmetra [Updated: 11:05 am, 9/30/10]
Jeff Eckman, CEO, BlueGreen Ventures
John Edwards, president, Adnexus Therapeutics
Bruce Eisen, retired [Added:10:10 am ET, 8/9/11]
Bonnie Fendrock, president and CEO, Hepregen
Crystal Ferguson, executive coordinator, corporate communications, Millennium: The Takeda Oncology Company [Added: 2 pm, 3/29/10]
John Fernberg, director of operations, Biogen Idec
Charles (Chuck) Finn, co-founder, president and CEO, RRD International
Lori Fitz, principal research scientist, inflammation and immunology, Pfizer [Added: 11:15 am, 6/2/10]
Bill Fleming, IT senior engineer, regional client computing, Pfizer [Added: 12:05 am, 4/2/10]
Barry Foster, retired [Added: 6:40 pm, 7/23/10]
Lynette Fouser, Principal Research Scientist II, Pfizer [Added: 9:35 pm 11/21/10]
Ed Fritsch, consultant
L. Patrick Gage, founder, enGage Biotech Consulting; executive chairman, Virdante Pharmaceuticals; board member, Acceleron Pharma, Immune Control, and Alvine Pharmaceuticals. Chairman of Cytokinetics. [Updated: 9:45 pm, 3/22/10]
Marc Garnick, clinical professor, Harvard Medical School
Derick Gates, senior director, global CMC, Pfizer [Added: 11:59 pm, 3/30/10]
Jill Goddard, associate Director, clinical operations, Infinity Pharmaceuticals [Added: 9:45 pm, 3/22/10]
Jane Davis Golden, director, clinical development, Virdante Pharmaceuticals [Added: 10:05 am, 3/23/10]
Jennifer Sydney Goldman, director, clinical business operations, Aveo Pharmaceuticals [Added: 9:45 pm Eastern, 3/22/10]
David Graham, vice president of program and alliance management, Aveo Pharmaceuticals
George Green, head of global manufacturing, technology development, Novartis Vaccines and Diagnostics
Scott Greer, managing director, Numenor Ventures, founder of Abgenix
Nick Guise, consultant, CNG Consultants
Tuan Ha-Ngoc, CEO, Aveo Pharmaceuticals
Alan Harris, executive director & global franchise head neuroscience and ophthalmology, Novartis Biologics
Dana Helm, independent human resources consultant
Rod Hewick, retired
Geoffrey Hodge, vice president of process development and technology, Xcellerex
Brian Hubbard, scientific executive director, Amgen
Tina Hurley, director, product development, Biogen Idec [Added: 10:40 am, 5/20/10]
Ben Isaacs, co-founder and president, Formatech
Indu Isaacs, co-founder and CEO, Formatech
Mary Antoinette Jackson, manager, global information services, Vertex Pharmaceuticals [Added: 3:35 pm, 10/19/11]
Ken Jacobs, director of project management, ImmunoGen
Niall Johnson, consultant
Jerry Justin, senior director of manufacturing operations, Shire Human Genetic Therapies
Robert Kamen, board member, Lycera
Nancy Kaplan, city councilor, Burlington VT [Added: 12:20 pm, 8/12/10]
Randal Kaufman, professor of biological chemistry and internal medicine, University of Michigan
Bob Kay, president and CEO, Origen Therapeutics
Ellen Keenan, senior administrative specialist, Pfizer (retiring April 1, 2010) [Added: 12:40 pm, 3/25/10]
Brian Kelley, vice president of bioprocess development, Genentech
Rich Kenley, CEO, Advantar Laboratories
Tim Keutzer, director of project management, Cubist Pharmaceuticals [Added: 9 am, 3/24/10]
Neil Kirby, CEO, Edimer Pharmaceuticals
Bob Kitchen, principle research scientist I, analytical research and development, Pfizer [Added: 6:30 pm, 3/31/10]
Jeanette Kohlbrenner, vice president of human resources, Infinity Pharmaceuticals
Mick Koplove, retired [Added: 6:40 pm, 7/23/10]
John Knopf, founder and CEO, Acceleron Pharma
Maryann Krane, regulatory consultant, RRD International
Cathy Lagana, quality assurance metrology engineer, Boston Analytical
Tina Lampropoulos, manager, regulatory publishing, Shire Human Genetic Therapies
Toni LaPorte, vendor manager, Biogen Idec [Added: 11:30 am, 3/2/2011]
Glenn Larsen, chief operating officer, Hydra Biosciences
Peter Lasky, senior vice president of human resources, Shire Pharmaceuticals [Added: 9 am, 3/24/10]
Ed LaVallie, associate director, global biotherapeutic technologies, Pfizer [Added, 3:10 pm, 7/27/10]
Dan Lavin, senior principal process engineer, Parsons
Steven Lazar, principal, SRL Patents & Licensing
Bruce Leicher, senior vice president and general counsel, Momenta Pharmaceuticals
Patricia Lewis, biotech/pharma consultant
Jian-Liang Li, manager, bioinformatics, Sanford Burnham Medical Research Institute [Added: 10:30 am, 3/9/11]
Melinda Lindquist, president, InforMEDical Communications
Vincent Ling, head of biological sciences, Neurotech [Added: 9:30 am, 1/24/11]
Jay Lochhead, director of manufacturing, Amgen [Added: 6:30 pm, 3/23/10]
William Lonergan, security consultant, owner, Lighthouse Security Consulting [Added: 10:10 am, 3/23/10]
Andy Long, senior scientist III, immunoscience pharmacology, Abbott Laboratories. [Added: 1:50 pm, 7/23/10]
Trish Lowden, principal research associate, Acceleron Pharma [Added: 5:30 pm, 5/19/10]
Tom Maniatis, professor of molecular and cellular biology, Harvard University, co-founder Sirtris Pharmaceuticals
Istvan Mazsaroff, scientific director, Taligen Therapeutics
Jim McColgan, associate director, pilot lab and production operations, Pfizer Global Manufacturing [Added: 7:45 pm, 3/23/10]
John McCoy, chief scientific officer, Glycosyn
Pamela McMahon, associate director, Institute for Technology Assessment, Massachusetts General Hospital [Added: 8/27/12]
David Merberg, associate director, knowledge management, Vertex Pharmaceuticals
Janet Judd Merrill, executive sales representative, molecular & cell biology systems, Life Technologies [Added: 11:05 am, 4/7/10]
Deborah Meshulam, director of process science and engineering, ImmunoGen
Rachel Meyers, senior director, RNAi lead development, Alnylam Pharmaceuticals
Stephen Meyler, director of portfolio and project Management, Pfizer BioTherapeutics [Added: 6:40 pm, 9/27/10]
Carol Miceli, senior manager, investor relations, Amag Pharmaceuticals
Clare Midgley, consultant, Denneen & Company
David Miller, senior director, business development, Dicerna Pharmaceuticals [Added: 9:05 pm, 3/28/10]
Doug Miller, director, Amgen
Jackie Millinor, executive coordinator, Cubist Pharmaceuticals [Added: 2:30 pm, 5/21/10]
Cheryl Milroy, human resources manager, RISI [Added: 2:30 pm, 8/15/10]
Tracy (Smith) Mitchell, senior scientist, pharmacology, Adnexus Therapeutics [Added: 3 pm, 5/21/10]
Jack Morgan, Acceleron Pharma
George Morris, director, information technology, Weld Hill Research Center & Arnold Arboretum of Harvard University [Added: 2:10 pm, 3/25/10]
John Morris, associate director, Pfizer [Added: 10:45 am, 3/25/10]
Allan Mufson, chief, cancer immunology and hematology branch, division of cancer biology, National Cancer Institute
Andrea Murphy, senior audit manager, Pfizer [Added: 6:45 pm, 10/22/10]
Kristin Murray, senior manager, global regulatory affairs, Pfizer [Added: 12:30 pm, 3/29/10]
Patricia Murtha-Riel, deceased [Added: 9:35 am, 1/24/11]
Armen Nahabedian, director, global engineering, Pfizer [Added: 7 pm, 4/2/10]
Steve Neben, senior director, project alliance and management, AnaptysBio [Added: 12:45 pm, 12/29/11]
Tammy Neben, research scientist, AnaptysBio [Added: 12:45 pm, 12/29/11]
Justin Neway, chief science officer, Aegis Analytical
Elliott Nickbarg, senior principal scientist,Merck Research Labs [Added: 11:40 am, 6/24/10]
Alexandria Niedzwiecki, legal counsel, Ab Initio Software [Added: 4:55 pm, 10/14/11]
Marie Noel, manager of employee benefits, Vertex Pharmaceuticals [Added: 2:30 pm, 8/15/10]
Marianne Nowacki, associate director of materials management, Shire Human Genetic Therapies
Gina Nugent, senior leader, The Yates Network
Pete Oakes, senior project manager, Pfizer [Added: 1:35 pm, 3/25/10]
Ellie Oberbeck, retired, former secretary to CEO Gabe Schmergel [Updated: 12:30 pm, 9/17/11]
Tom O’Brien, associate director, QA, Pfizer [Added: 2 pm, 4/2/10]
Doug Owen, drug and biologic regulatory affairs consultant
Peri Ozker, acupuncturist and owner, Peri Ozker Acupuncture [Added: 6:20 pm, 3/23/10]
Sharan Pagano, vice president of scientific alliances, Rosa Drug Development Advisors [Updated: 8:45 am, 3/9/11]
Michelle Palmer, director of screening, chemical biology, Broad Institute of MIT and Harvard; president-elect, Society for Biomolecular Sciences
Annamaria Paone, drug supply manager, ArQule [Added: 1:35 pm, 10/4/10]
Gabriela Paredes, consultant, GSP Consulting
Adelene Perkins, CEO, Infinity Pharmaceuticals
Christopher Perley, vice president and general manager of Devens biologics manufacturing facility, Bristol-Myers Squibb
Julie (Manousos) Petros, ABA Special Education Assistant, Town of Andover, MA [Added: 3:40 pm, 5/3/10]
John Pettricciani, biotechnology consultant
Terri Phaneuf, lead investigator IV, APO compliance, Pfizer [Added: 10:15 am, 4/20/10]
Mike Philbrook, director, drug delivery discovery, Genzyme [Added: 5:10 pm, 3/24/10]
Ross Phillips, independent biotechnology professional
Janet Pohlod, district manager-west, Celgene
Steve Potter, associate director, facilities and supply chain operations, Baxter Bioscience [Added: 9:40 am, 1/24/11]
Bill Powers, logistics manager, Alnylam Pharmaceuticals
Carolyn Pratt, executive vice president, RRD International
Mark Ptashne, molecular biologist, Memorial Sloan-Kettering Cancer Center
Praveena Raman, senior information specialist, Elan Pharmaceuticals [Added: 12:50 pm, 3/23/10]
Bernardo Perez-Ramirez, senior scientific director, bioformulations development, Genzyme [Added: 4:30 pm, 3/24/10]
Manish Ranjitkar, quality assurance manager, Vertex Pharmaceuticals
Kathy Reckendorf, senior documentation associate, Millennium: The Takeda Oncology Company [Added: 6:30 pm, 3/31/10]
Christine Resmini, scientist, RXi Pharmaceuticals [Added: 1:40 pm, 10/4/10]
Richard Resnick, CEO, GenomeQuest [Added: 11:10 am, 11/22/11]
Tom Reynolds, senior director of IT, Tolerx
Troy Richards, CMC project manager, Vaccinex [Added: 4:30 pm, 3/24/10]
Rod Riedel, vice president of regulatory affairs, Momenta Pharmaceuticals
Chris Riel, director, quality assurance global compliance operations, Shire HGT [Added: 9:35 am, 1/24/11]
Cheryl Riel, senior manager, nonclinical writing, Millennium: The Takeda Oncology Company [Added: 6:30 pm, 3/31/10]
Ilonna Rimm, senior vice president, director of physician consultation services, Lazard Capital Markets [Added: 2:08 pm, 3/23/10]
John Ripple, CEO, Virdante Pharmaceuticals
Jeff Robinson, head of downstream MSAT, Lonza New England Organization [Added: 2:10 pm, 4/5/10]
Susan Rogers, pharma, IT project management consultant and certified business coach [Added: 10:50 am, 3/24/10]
Eyal Ron, owner, consultant, MADASH [Added: 4:30 pm, 3/24/10]
Vicki Rosen, professor and chair, developmental biology, Harvard University School of Dental Medicine [Added: 6:20 pm, 3/23/10]
Anthony Rotunno, vice president of U.S. Microbial operations, Lonza
David Rozzell, president and CEO, Solidius Biosciences
Kim Rubin, consultant
John Ryan, chief medical officer, Cerulean Pharma
Pat Sacco, vice president of facilities and engineering technical services, acting/interim VP of manufacturing, Shire Human Genetic Therapies [Added: 6:40 pm Eastern, 9/27/10]
Cynthia Sarnoski, retired [Added: 6:40 pm, 7/23/10]
Robert Schaub, senior vice president of discovery and development, Archemix
Neil Schauer, director of DSP research and development, Millipore
Mark Schiavone, tech scientist IV, Pfizer [Added: 2:20 pm, 8/10/10]
Andrea Schievella, business manager, Cancer Research Technology
Jerry Schindler, vice president, biostatistics and research decision sciences, late development statistics, Merck Research Laboratories [Added: 2:20 pm, 3/24/10]
Gabriel Schmergel, board member, PerkinElmer, board member Tufts University Veterinary School
Holly White Schmidt, scientist, discovery protein sciences, Adnexus Therapeutics [Added: 2:30 pm, 5/21/10]
Jay Schrier, senior director, pharmaceutical development, Pacira Pharmaceuticals [Added: 5:30 pm, 3/24/10]
Ullrich Schwertschlag, chief medical officer, Attogen
Steve Scott, director of new product opportunities, GE Healthcare
Jasbir Seehra, founder and chief scientific officer, Acceleron Pharma
Susan Severance, research project manager/research associate, Oregon Health & Science University [Added: 3:10 pm, 10/7/10]
Gray Shaw, co-founder, Aarvon Biosciences
Richard Shea, chief financial officer, Momenta Pharmaceuticals
Todd Shegog, senior vice president of finance and chief financial officer, Millennium: The Takeda Oncology Company
Matt Sherman, chief medical officer, Acceleron Pharma
Charles Shoemaker, professor, Division of Infectious Diseases, Department of Biomedical Sciences, Tufts Cummings School of Veterinary Medicine [Added: 9:45 pm, 3/22/10]
Mary Simchik, senior EH&S specialist II, Pfizer [Added: 2 pm, 4/2/10]
Martin Sinacore, associate director cell culture development, site head, Biogen Idec
Christine Soter, manager, documentation and compliance, Biogen Idec [Added: 7:05 pm, 4/12/10]
Jennifer Smith, senior director, quality, Momenta Pharmaceuticals [Added: 10:30 am, 3/26/10]
Colleen Surrette Sproul, principal, Contracts Associates [Added: 12:10 pm, 10/28/10]
Mark Stahl, director of protein engineering, global biotherapeutics technologies, Pfizer [Added: 8:20 am, 10/27/10]
Lawrence Stein, former general counsel, Wyeth
Bob Steininger, senior vice president of manufacturing, Acceleron Pharma
Neil Steinmeyer, senior research scientist II, analytical research and development, Pfizer [Added: 1 pm, 4/5/10]
Dave Stepp, principal scientist, Genzyme
David Stone, managing director, Liberty Tree Advisors
Jay Stoudemire, senior preclinical development expert
Lauri Sweeney, senior clinical trial manager, Biogen Idec [Added: 2:30 pm, 5/21/10]
Mary Switzer, senior research scientist II, Pfizer [Added: 10:30 am, 3/26/10]
Pam Szklut, principal research scientist II, Pfizer [Added: 1:45 pm, 3/25/10]
Bruce Tangarone, principle research scientist I, analytical research and development, Pfizer [Added: 6:30 pm, 3/31/10]
Scott Thies, senior director of stem cell biology, Fate Therapeutics
Gregg Timony, director of preclinical sciences, Receptos [Added: 9 am, 3/24/10]
Carol Tranfaglia, manager of clinical data development, Cell Therapeutics
Greg Tucker-Kellogg, chief technology officer, and senior director systems biology, Lilly Singapore Centre for Drug Discovery
Katherine Turner, biotechnology professional
Victor Van Cleave, vice president of research and development, Meridien Life Science
James Vath, head of discovery and development, Zafgen
Jennifer Vath, independent pharmaceuticals professional
Trudi Veldman, director of biologics generation, Abbott Bioresearch Center
Jessica Vozella, senior contract and licensing attorney, LCLS [Added: 8:10 pm, 3/2/12]
Chris Wang, senior clinical research scientist, Novartis Vaccines and Diagnostics
Jack Wang, associate director, Adnexus Therapeutics
Nadine Weich, biopharmaceutical R&D professional
Jim Whalen, president, ANOVA Pharma Consultancy [Added: 3:35 pm 5/20/10]
Rick Williams, senior project manager, process transfer and manufacturing, Pfizer. Retiring April 30, 2010 [Added: 12:05 am, 4/2/10]
Mark Williamson, medical science liaison, Millennium: The Takeda Oncology Company
Dwight Winters, senior scientist, Amgen [Added: 11:30 am, 6/1/10]
JoAnn Witek, senior scientist and director, cell biology, Hydra Biosciences [Added: 12:50 pm, 3/23/10]
Roslynn Witte, regional director, hematology, Pfizer Pharmaceuticals [Added: 10:30 am, 3/26/10]
Steve Wolpe, senior vice president of research, Noble Life Sciences [Updated: 1:40 pm, 10/15/11]
Gordon Wong, vice president of new ventures, Biogen Idec
Clive Wood, senior vice president and head, global biologics, Bayer Schering Pharma [Added: 9:45 pm Eastern, 3/22/10]
Becky Woodcock, manager of coagulation products, CSL Behring
Mary Beth Woodin, president at MBK Associates and Menopause Alliance [Added: 9 am, 3/24/10]
Michele (Koethe) Yetman, vice president of human resources for technology, Amazon.com
Scott Young, chief operating officer, Link Medicine [Added: 11:30 am, 11/08/10]
